Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Published:2019-08 Issue:8 Volume:6 Page:e419-e428
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Davids Matthew S,Brander Danielle M,Kim Haesook T,Tyekucheva Svitlana,Bsat Jad,Savell Alexandra,Hellman Jeffrey M,Bazemore Josie,Francoeur Karen,Alencar Alvaro,Shune Leyla,Omaira Mohammad,Jacobson Caron A,Armand Philippe,Ng Samuel,Crombie Jennifer,LaCasce Ann S,Arnason Jon,Hochberg Ephraim P,Takvorian Ronald W,Abramson Jeremy S,Fisher David C,Brown Jennifer R

Funder

Leukemia & Lymphoma Society

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Chronic lymphocytic leukaemia;Hallek;Lancet,2018

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

3. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst;Lancet Oncol,2016

4. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL;Thompson;Blood,2016

5. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

2. Chronic lymphocytic leukaemia;The Lancet;2024-08

3. Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma;Frontiers in Cardiovascular Medicine;2024-07-26

4. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study);British Journal of Haematology;2024-04-23

5. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL;Blood Advances;2024-02-14